Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3399-3402

  Volm, M ^a   Zintl, F ^b   Sauerbrey, A ^b   Koomagi R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b German Cancer Research Center ^*

Author keywords

Childhood ALL; Fas ligand; Immunocytochemistry; Prognostic value

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FAS LIGAND; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

BLOTTING, WESTERN; CHILD; DISEASE-FREE SURVIVAL; FAS LIGAND PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, LYMPHOCYTIC, ACUTE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROGNOSIS; TIME FACTORS;

EID: 0033404722     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sauerbrey A, Zintl F and Volm M: P-glycoprotein and glutathione S-transferase in childhood acute lymphoblastic leukemia. Br J Cancer 70: 1144-1144, 1994.
2. Volm M, Zintl F, Edler L and Sauerbrey A: Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia. Med Pediatr Oncol 28: 117-126, 1997.
3. Volm M and Mattern J: Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncogenesis 7: 227-244, 1996.
4. Desoize B: Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14: 2291-2294, 1994.
5. Bhalla K, Ibrado AM, Toukina E, Tang C, Mahoney ME, and Huang Y: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia. Leukemia 7: 563-568, 1993.
6. Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed MR and Darzynkiewicz Z: Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 7: 659-670, 1993.
7. Carson AD and Ribeiro JM: Apoptosis and diseases. The Lancet 341: 1251-1253, 1993.
8. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
9. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
10. Nagata S and Golstein P: The Fas death factor. Science 267: 1451-1455, 1995.
11. Xerri L, Devilard E, Hassoun J, Mawas C and Birg F: Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. J Clin Pathol: Mol Pathol 50: 87-91, 1997.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR and Sultan C: French-American-British (FAB) cooperative group. Proposal for the classification of the acute leukaemias. Br J Haematol 33: 451-458, 1976.
13. Zintl F, Malke H, Reimann M, Domula M, Dörffel W, Eggers G, Exadaktylos P, Hilgenfeld E, Kotte W, Krause I, Kunert W, Mittler U, Möbius D, Reddemann H, Weinmann G and Weissbach G: Results with randomized BFM adopted studies for ALL therapy in childhood in East German countries. Acute Leukemias IV: Prognostic factors (ed. by T. Büchner G, Schellong W, Hiddemann J, Urbanitz J and Ritter J), pp 179-186, Springer Berlin, 1993.
14. Volm M, Sauerbrey A and Zintl F: Prognostic significance of protein kinase C in newly diagnosed childhood acute lymphoblastic leukemia. Int J Oncol 4: 363-368, 1994.
15. Volm M, Sauerbrey A, Stammler G and Zintl F: Detection of Fos, Jun and Ras in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and PCR. Int J Oncol 4: 1251-1256, 1994.
16. Krehan A, Lorenz P, Plana-Coll M and Pyerin W: Interaction sites between catalytic and regulatory subunits in human protein kinase CK2 holoenzymes as indicated by chemical cross-linking and immunological investigations. Biochemistry 35: 4966-4975, 1996.
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1956.
18. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
19. Tanaka M, Itai T, Adachi M and Nagata S: Down-regulation of Fas ligand by shedding. Nature Med 4: 31-36, 1998.
20. Cai Z, Stancou R, Körner M and Chouaib S: Impairment of Fas antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 4: 535-546, 1997.
21. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 6: 921 -926, 1996.
22. Villunger A, Egle A, Kos M Hartmann BL, Geley S, Kofler R and Greil R: Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 57: 3331-3334, 1997.
23. Friesen C, Fulda S and Debatin KM: Deficient activation of the CD95 (Apo-1/Fas) system in drug-resistant cells. Leukemia 11: 1833-1841, 1997.
24. Friesen C, Herr I, Kramer PH and Debatin KM: Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in leukemic cells. Nature Med 2: 574-577, 1996.
25. Min YH, Lee S, Lee JW, Chong SY, Hahn J and Ko YW: Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Br J Haematol 93: 928-930, 1996.